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Abstract: Omega-3 (ω-3) fatty acids are one of the two main families of long chain 
polyunsaturated fatty acids (PUFA). The main omega-3 fatty acids in the mammalian  
body are α-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA). Central nervous tissues of vertebrates are characterized by a high concentration of 
omega-3 fatty acids. Moreover, in the human brain, DHA is considered as the main 
structural omega-3 fatty acid, which comprises about 40% of the PUFAs in total. DHA 
deficiency may be the cause of many disorders such as depression, inability to concentrate, 
excessive mood swings, anxiety, cardiovascular disease, type 2 diabetes, dry skin and so 
on. On the other hand, zinc is the most abundant trace metal in the human brain. There are 
many scientific studies linking zinc, especially excess amounts of free zinc, to cellular 
death. Neurodegenerative diseases, such as Alzheimer’s disease, are characterized by 
altered zinc metabolism. Both animal model studies and human cell culture studies have 
shown a possible link between omega-3 fatty acids, zinc transporter levels and free zinc 
availability at cellular levels. Many other studies have also suggested a possible omega-3 
and zinc effect on neurodegeneration and cellular death. Therefore, in this review, we will 
examine the effect of omega-3 fatty acids on zinc transporters and the importance of free 
zinc for human neuronal cells. Moreover, we will evaluate the collective understanding of 
mechanism(s) for the interaction of these elements in neuronal research and their 
significance for the diagnosis and treatment of neurodegeneration. 
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1. Introduction 
Fish is known as the food for the brain. Although this saying has been around for decades, 
understanding of the molecular mechanism(s) of fish oil (or more specifically omega-3 fatty acids) in 
promoting neuronal wellbeing has not been great until recently. With the increase in neurodegenerative 
diseases globally, many research groups are attempting to gain a better understanding of the molecular 
detail of this mechanism, and have made some breakthroughs in recent years [1–8]. In this article, we 
review key findings on the effect of the omega-3 fatty acid DHA on zinc transporters and the 
importance of free zinc to human neuronal cells. Furthermore, this review article identifies research 
areas that are in need of further study. 
2. Fatty Acids 
Epidemiological studies have linked high intake of fish and shellfish as part of the daily diet to 
reduction of the incidence and/or severity of Alzheimer’s disease (AD) and senile mental decline in 
general [3]. Many studies over the past few decades have shown the nutritional value of fish, 
particularly in regard to omega-3 fatty acids [4]. Omega-3 fatty acids are one of the two main families 
of a broader group of fatty acids referred to as polyunsaturated fatty acids (PUFAs). The other main 
family of PUFAs encompasses the omega-6 fatty acids. In general, PUFAs are essential in many 
biochemical events, especially in early post-natal development processes such as cellular differentiation, 
photoreceptor membrane biogenesis and active synaptogenesis [9]. Despite the significance of these 
two families, mammals cannot synthesize PUFA de novo, so they must be ingested from dietary 
sources. Though belonging to the same family, both omega-3 and omega-6 fatty acids are 
metabolically and functionally distinct and have opposing physiological effects. In the human body, 
high concentrations of omega-6 fatty acids are known to increase the formation of prostaglandins and 
thereby increase inflammatory processes [10]. On the other hand, the reverse process can be seen with 
increased omega-3 fatty acids in the body. Many other factors, such as thromboxane A2 (TXA2), 
leukotriene B4 (LTB4), IL-1, IL-6, tumor necrosis factor (TNF) and C-reactive protein, which are 
implicated in various health conditions, have been shown to be increased with high omega-6 fatty 
acids but decreased with omega-3 fatty acids in the human body [10]. 
Dietary fatty acids have been identified as protective factors in coronary heart disease [11], and 
PUFA levels are also known to play a critical role in immune responses, gene expression and 
intercellular communications [12]. Mainly, omega-3 fatty acids are known to be vital in the prevention 
of fatal ventricular arrhythmias [13]. Omega-3 fatty acids are also known to reduce thrombus 
formation propensity by decreasing platelet aggregation, blood viscosity and fibrinogen levels [14]. 
Since omega-3 fatty acids are prevalent in the nervous system, it seems logical that a deficiency may 
result in neuronal problems, and this is indeed what has been identified and reported in the  
literature [15–20]. The main omega-3 fatty acids in the mammalian body are α-linolenic acid (ALA), 
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docosahexenoic acid (DHA) and eicosapentaenoic acid (EPA). In general, seafood is rich in  
omega-3 fatty acids, more specifically DHA and EPA (Table 1). Thus far, there are nine separate 
epidemiological studies that suggest a possible link between increased fish consumption and reduced 
risk of AD [15] and eight out of ten studies have reported a link between higher blood omega-3 levels 
and reduced cognitive decline [16]. In another study conducted with individuals of 65 years of age or 
older (n = 6158), it was found that only high fish consumption, but not dietary omega-3 acid intake, 
had a protective effect on cognitive decline [17]. In 2005, following a meta-analysis study of the 
available epidemiology and preclinical studies, clinical trials were conducted to assess the effects of 
omega-3 fatty acids on cognitive protection [18]. Four of the trials completed have shown a protective 
effect of omega-3 fatty acids only among those with mild cognitive impairment conditions [19].  
In another trial with 485 subjects with mild memory complaints, an improvement with 900 mg of 
DHA was demonstrated [20]. 
Table 1. Total percentage of omega-3 fatty acids in common foods and supplements.  
Table adopted from Maclean C.H. et al. [18]. 
Food/Supplement EPA DHA ALA Total % 
Fish     
Salmon X X  >50% 
Sardine X X  >50% 
Anchovy X X  >50% 
Halibut X X  >50% 
Herring X X  >50% 
Mackerel X X  >50% 
Tuna X X  >50% 
Fresh Bluefin X X  >50% 
Oils/Supplements     
Fish oil capsules X X  >50% 
Cod liver oils X X  >50% 
Salmon oil X X  >50% 
Sardine oil X X  >50% 
Black currant oil    X 10%–50% 
Canola oil   X 10%–50% 
Mustard seed oils    X 10%–50% 
Soybean oil    X 10%–50% 
Walnut oil   X 10%–50% 
Wheat germ oil   X 10%–50% 
Seeds and other foods     
Flaxseeds/Linseeds   X >50% 
Spinach   X >50% 
Wheat germ   X 10%–50% 
Human milk   X 10%–50% 
Peanut butter    X <10% 
Soybeans    X <10% 
Olive oil    X <10% 
Walnuts   X <10% 
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DHA is the most abundant fatty acid in neural membranes, imparting appropriate fluidity and other 
properties [21], and is thus considered as the most important fatty acid in neuronal studies [8]. DHA is 
well conserved throughout the mammalian species despite their dietary differences [22]. DHA is 
mainly concentrated in membrane phospholipids at synapses and in retinal photoreceptors [23] and 
also in the testis and sperm [22]. In adult rats’ brain, DHA comprises approximately 17% of the total 
fatty acid weight, and in the retina it is as high as 33% [24]. DHA is believed to have played a major 
role in the evolution of the modern human and in particular the well-developed brain [25]. Premature 
babies fed on DHA-rich formula show improvements in vocabulary and motor performance [26]. 
Analysis of human cadaver brains have shown that people with AD have less DHA in their frontal lobe 
and hippocampus compared with unaffected individuals [27]. Furthermore, studies in mice have 
increased support for the protective role of omega-3 fatty acids. Mice administrated with a dietary 
intake of DHA showed an increase in DHA levels in the hippocampus. Errors in memory were 
decreased in these mice and they demonstrated reduced peroxide and free radical levels [28], 
suggesting a role in antioxidant defense. Another study conducted with a Tg2576 mouse model of  
AD demonstrated that dietary DHA supplementation had a protective effect against reduction in 
drebrin (actin associated protein), elevated oxidation, and to some extent, apoptosis via decreased 
caspase activity [29]. 
3. Zinc and Life 
Zinc is a trace element, which is indispensable for life, and it is the second most abundant trace 
element in the body [30]. Zinc is known to be related to growth, development, differentiation, immune 
response, receptor activity [31], DNA synthesis, gene expression, neuro-transmission, enzymatic 
catalysis, hormonal storage and release, tissue repair, memory, the visual process [32] and many other 
cellular functions. Moreover, the indispensability of zinc to the body can be discussed in many other 
aspects, including as a component of over 300 different enzymes [33] or as an integral component of a 
metallothioneins [34] or as a gene regulatory protein [35]. Approximately 3% of all proteins contain 
zinc binding motifs [36]. The broad biological functionality of zinc is thought to be due to its stable 
chemical and physical properties [37]. Zinc is considered to have three different functions in enzymes; 
catalytic, coactive and structural [38]. Indeed, it is the only metal found in all six different subclasses 
of enzymes [39]. The essential nature of zinc to the human body can be clearly displayed by studying 
the wide range of pathological effects of zinc deficiency. Anorexia, embryonic and post-natal growth 
retardation, alopecia, skin lesions, difficulties in wound healing, increased hemorrhage tendency and 
severe reproductive abnormalities, emotional instability, irritability and depression are just some of the 
detrimental effects of zinc deficiency [31,33,40–43]. 
Proper development and function of the central nervous system (CNS) is highly dependent on zinc 
levels. In the mammalian organs, zinc is mainly concentrated in the brain at around 150 µm [33]. 
However, free zinc in the mammalian brain is calculated to be around 10 to 20 nm [44,45] and the rest 
exists in either protein-, enzyme- or nucleotide bound form [31]. The brain and zinc relationship is 
thought to be mediated through glutamate receptors [30], and zinc is known to inhibit both excitatory 
and inhibitory receptors [36]. Vesicular localization of zinc in pre-synaptic terminals is a characteristic 
feature of brain-localized zinc, and its release is dependent on neural activity [30]. Zinc deficiency is 
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also related to many CNS abnormalities. Retardation of the growth and development of CNS  
tissues have been linked to low zinc levels [38]. Peripheral neuropathy, spina bifida, hydrocephalus, 
anencephalus [46], epilepsy and Pick’s disease [47] have also been linked to zinc deficiency. 
Although zinc deficiency causes much damage to the body, the body cannot tolerate excessive 
amounts of zinc. In both human and animal cells, neurotoxicity and neurodegeneration are widely seen 
with high levels of zinc [30,48,49]. Translocation of zinc from pre-synaptic to post-synaptic neurons  
is the main mechanism thought to be effected in neurotoxicity, epilepsy [47] and brain trauma [50].  
The relationship between zinc and neurodegeneration, specifically AD, has been interpreted in several 
ways. One study has proposed that β-amyloid has a greater propensity to form insoluble amyloid in the 
presence of high physiological levels of zinc [51]. Insoluble amyloid is thought to aggregate to form 
plaques, which is a main pathological feature of AD [52]. Further studies have shown that chelation of 
zinc ions can deform and disaggregate plaques [53]. In AD, the most prominent injuries are found in 
hippocampal pyramidal neurons, acetylcholine-containing neurons in the basal forebrain, and in 
somatostatin-containing neurons in the forebrain [30]. All of these neurons are known to favor  
rapid and direct entry of zinc in high concentrations [54], leaving neurons frequently exposed to high 
dosages of zinc. This is thought to promote neuronal cell damage through oxidative stress and 
mitochondrial dysfunction [30]. 
Excessive levels of zinc are also capable of inhibiting Ca2+ and Na+ voltage gated channels [55–57] 
and up-regulating the cellular levels of reactive oxygen species (ROS) [58]. Elevated ROS levels are 
directly detrimental to cell survival by damaging key macromolecules such as nucleic acids, proteins 
and lipids, which results in rapid cell death. Moreover, high levels of zinc are found in Alzheimer’s 
brains indicating a possible zinc related neurodegeneration [30]. A study conducted with mouse 
neuronal cells has shown that even a 24-h exposure to high levels of zinc (40 µm) is sufficient to 
degenerate cells [59]. 
Although it is vital to regulate and maintain zinc levels in the human body, assessment of the zinc 
status is not an easy task [60]. This is mainly due to the lack of a specific and sensitive biochemical 
index of zinc nutrition. Owing to its indispensable nature, many organisms are capable of maintaining 
zinc homeostasis despite a low dietary intake. If the human diet is deficient in zinc, the body 
efficiently conserves zinc at the tissue level by compensating other cellular mechanisms to delay the 
dietary deficiency effects of zinc. These include reduction of cellular growth rate and zinc excretion 
levels, and redistribution of available zinc to more zinc dependent cells or organs [61,62]. Plasma or 
serum zinc is the most commonly used marker to assess the zinc levels, however plasma and serum 
zinc levels are known to be relatively insensitive to dietary zinc. More recently, a novel method of 
measuring metallothionein (MT) levels was introduced as a more reliable alternative. Although it 
shows promise as a biomarker, more research is required to determine the specificity of MT for the 
assessment of the zinc status of individuals and populations. In humans, erythrocyte metallothionein 
(E-MT) levels may be considered as a better indicator of zinc depletion and repletion, as E-MT levels 
are sensitive to dietary zinc intake [60,63,64]. Once again, further research is required to assess E-MT 
as a specific biomarker for zinc status. However, it should be noted here that MT plays an important 
role in zinc homeostasis by acting as a target for zinc ion binding and thus assisting in the trafficking 
of zinc ions through the cell, which may be similar to that of zinc transporters as discussed in  
Section 4 below. 
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4. Zinc Transporters 
As discussed in Section 3 above, deficient or excess amounts of zinc in the body can be catastrophic 
to the integrity of cellular biochemical and biological systems, indicating the necessity for an appropriate 
and sophisticated homeostatic mechanism. Primarily, this is achieved by the gastrointestinal system 
controlling the absorption, excretion and the distribution of zinc [65], although the hydrophilic and 
high-charge molecular characteristics of zinc are not favorable for passive diffusion across the cell 
membranes [66]. Thus, in most, if not in all of these mechanisms, zinc movement is known to occur 
via intermembrane proteins and zinc transporter (ZnT) proteins [67]. These transporters are mainly 
categorized under two metal transporter families; Zip (ZRT, IRT like proteins) and CDF/ZnT (Cation 
Diffusion Facilitator) [67]. Both families are also known as SLC (Solute Linked Carrier) gene 
families: Zip (SLC-39) and ZnT (SLC-30) [68]. More than 20 zinc transporters have been identified 
and characterized over the last two decades (14 Zips and 8 ZnTs) [67,68]. 
Members of the SLC39 family have been identified as the putative facilitators of zinc influx into  
the cytosol, either from the extracellular environment or from intracellular compartments (Figure 1).  
The identification of this transporter family was a result of gene sequencing of known Zip1 protein 
transporters in plants, yeast and human cells [69]. In contrast to the SLC39 family, the SLC30 family 
facilitates the opposite process, namely zinc efflux from the cytosol to the extracellular environment or 
into luminal compartments such as secretory granules, endosomes and synaptic vesicles; thus decreasing 
intracellular zinc availability (Figure 1) [70]. Despite the significant increase in the knowledge of these 
transporters over recent years, many aspects of the molecular mechanisms of zinc metabolism are yet 
to be understood. Out of all of the zinc transporters, ZnT3 is the most important in the brain where  
it is responsible for the transport of zinc into the synaptic vesicles of glutamatergic neurons in  
the hippocampus and neocortex, which will be discussed in detail in Section 5 below. 
Figure 1. Putative cellular localization of some of the different human zinc transporters  
(i.e., Zip1- Zip4 and ZnT1- ZnT7). Arrows indicate the direction of zinc passage by  
the appropriate putative zinc transporters in a generalized human cell. Although there are 
fourteen Zips and eight ZnTs known so far, only the main zinc transporters are illustrated 
in this figure for clarity and brevity. 
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5. DHA and Zinc Homeostasis 
Many studies have identified possible associations between DHA levels, zinc homeostasis, 
neuroprotection and neurodegeneration. Dietary DHA deficiency resulted in increased zinc levels in 
the hippocampus and elevated expression of the putative zinc transporter, ZnT3, in the rat brain [71]. 
In this study, rats were raised under control diets, which were either omega-3 enriched or  
DHA-deficient. Rats raised under the deficient diet demonstrated an up-regulation of ZnT3 mRNA 
levels and free zinc in the hippocampus. Although this study reports an increase in ZnT3 mRNA 
levels, it lacks protein data to assess the functionality or availability of the ZnT3 protein since changes 
at the RNA level do not necessarily equate to changes at the protein expression level. In addition, 
altered zinc metabolism in neuronal cells has been linked to neurodegenerative conditions such  
as AD [30]. Another study conducted with transgenic mice has shown a significant link between ZnT3 
transporter levels and cerebral amyloid plaque pathology. When the ZnT3 transporter was silenced in 
transgenic mice expressing cerebral amyloid plaque pathology, a significant reduction in plaque load 
and the presence of insoluble amyloid were observed [72]. In addition to the decrease in plaque load, 
ZnT3 silenced mice also exhibited a significant reduction in free zinc availability in the hippocampus 
and cerebral cortex. Collectively, the findings from this study are very interesting and indicate a clear 
connection between zinc availability and amyloid plaque formation, thus indicating a possible link to 
AD. DHA supplementation has also been reported to limit the following: amyloid presence, synaptic 
marker loss, hyper-phosphorylation of Tau, oxidative damage and cognitive deficits in transgenic 
mouse model of AD [73]. In addition, studies by Stoltenberg, Flinn and colleagues report on the 
modulation of zinc and the effect in transgenic mouse models of AD [74,75]. Given that all of these 
are classic pathological features of AD, and considering the limiting nature of DHA in these processes, 
it can be argued that DHA is a key candidate in preventing or even curing this debilitating disease. 
In order to better understand the possible links and pathways of zinc and DHA with 
neurodegeneration, we designed a study that incorporates all three of these aspects, to study their 
effects at the cellular level. In this study, we were able to demonstrate a possible link between omega-3 
fatty acid (DHA) concentration, zinc availability and zinc transporter expression levels in cultured 
human neuronal cells [7]. When treated with DHA over 48 h, ZnT3 levels were markedly reduced  
in the human neuroblastoma M17 cell line. Moreover, in the same study, we were able to propose  
a possible neuroprotective mechanism of DHA, which we believe is exerted through a reduction  
in cellular zinc levels (through altering zinc transporter expression levels) that in turn inhibits  
apoptosis [7]. DHA supplemented M17 cells also showed a marked depletion of zinc uptake (up  
to 30%) [7], and free zinc levels in the cytosol were significantly low compared to the control 
treatment (unpublished data). This reduction in free zinc availability was specific to DHA; cells treated 
with EPA had no significant change in free zinc levels (unpublished data). Moreover, DHA-repleted 
cells had low levels of active caspase-3 and high Bcl-2 levels compared to the control treatment [7]. 
These findings are consistent with previous published data and further strengthen the possible 
correlation between zinc, DHA and neurodegeneration [30,71–75]. On the other hand, recent studies 
using ZnT3 knockout (ZnT3KO) mice have shown the importance of ZnT3 in memory and AD 
pathology [76–78]. For example, Sindreu and colleagues have used ZnT3KO mice to establish the 
important role of ZnT3 in zinc homeostasis that modulate presynaptic MAPK signaling required for 
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hippocampus-dependent memory [76]. In another study using the ZnT3KO mice, it has been shown 
that ablation of ZnT3 may represent a phenocopy for the synaptic and memory deficits of AD [77]. 
Finally, with the use of the ZnT3KO mice, Martel and colleagues have shown that ZnT3 is involved in 
memory and behavior dependent on the hippocampus and perirhinal cortex [78]. Collectively, all  
of these three ZnT3KO mice studies indicate the important role of ZnT3 in memory [76–78]. 
However, further research is required to establish the relevance of such mouse model findings to the 
human system. 
As discussed above, due to the importance of zinc, especially labile zinc in cells and tissues, it is 
vital to have a comprehensive understanding of the concentration, distribution, localization, kinetics 
and functions of free zinc. Moreover, in a therapeutic sense, it will be beneficial to understand and 
develop mechanisms where the freely available zinc pool can be regulated. However, the mechanism 
by which DHA and zinc interact or effect neuronal cell survival is yet to be identified; although recent 
studies using cultured human neuronal cells (including studies from our research group), have been 
able to shed some light on this matter, as discussed above. Results from these studies indicate  
a possible zinc-transporter-expression-level-dependent mechanism for DHA neuroprotection. 
Collectively from these studies, the following possible mechanism can be proposed (Figure 2). 
Figure 2. Proposed neuroprotection mechanism of docosahexaenoic acid (DHA) in 
reference to synaptic zinc. Schematic diagram showing possible benefits of DHA in 
neuroprotection through reduction of ZnT3 transporter expression levels in human 
neuronal cells, which results in a reduction of zinc flux and thus lowering zinc 
concentrations in neuronal synaptic vesicles, and therefore contributing to a lower 
incidence of neurodegenerative diseases (ND), such as Alzheimer’s disease (AD). 
 
More recent data from our research group have also shown a link between the expression levels  
of histone H3 and H4 proteins in human neuronal cells in relation to DHA and zinc. Following DHA 
treatment, both H3 and H4 levels were up-regulated. In contrast, zinc treatment resulted in a  
down-regulation of histone levels [6]. Both zinc and DHA have shown opposing effects on histone  
post-translational modifications, indicating a possible distinctive epigenetic pattern [4]. Upon 
treatment with zinc, M17 cells displayed an increase in histone deacetylase (HDACs) and a reduction 
in histone acetylation. Conversely, with DHA treatment, HDAC levels were significantly reduced and 
the acetylation of histones was up-regulated [4]. These findings also support a possible interaction 
between DHA and zinc availability. 
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6. Conclusions and Future Perspectives 
Considering the large body of reported data and findings, it is possible to safely claim that there is 
more than one potential pathway by which DHA and zinc interact at a cellular level, at least in cultured 
human neuronal cells. Significance and importance of both DHA and zinc in neuronal survival is 
attested by the presence of these multiple mechanisms. Thus, this highlights the importance of greater 
molecular understanding of the subject matter and the need for further investigation. Most of these 
reported studies were conducted using human neuroblastoma cells, or similar cell types, due to the lack 
of live mature human neuronal cells. Thus, the results may differ from results achieved under actual 
human physiological conditions due to the structural and functional differences between these cells 
and mature human neurons. Therefore, an alternative approach that can mimic the human neuronal 
cells more effectively would be advantageous. For example, the use of differentiated neuroblastoma 
cells instead of undifferentiated cells might help to give a better and more appropriate insight into the 
discussed molecular mechanisms. 
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